BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/4/2014 5:33:00 PM | Browse: 458 | Download: 300
Publication Name World Journal of Gastroenterology
Manuscript ID 2554
Country/Territory Cuba
2013-02-28 16:35
Peer-Review Started
2013-04-03 11:49
To Make the First Decision
2013-05-14 19:00
Return for Revision
2013-05-27 10:48
2013-06-14 04:54
Second Decision
2013-07-12 16:45
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-07-13 01:02
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-11-28 17:06
Typeset the Manuscript
2013-12-25 16:48
Publish the Manuscript Online
2014-01-20 17:10
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Immunology
Manuscript Type Autobiography
Article Title HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin
Manuscript Source Invited Manuscript
All Author List Yalena Amador-Cañizares, Gillian Martínez-Donato, Liz Álvarez-Lajonchere, Claudia Vasallo, Mariacarla Dausá, Daylen Aguilar-Noriega, Carmen Valenzuela, Ivette Raíces, Jean Dubuisson, Czeslaw Wychowski, Zurina Cinza-Estévez, Marlén Castellanos, Magdalys Núñez, Anny Armas, Yaimé González, Ismariley Revé, Ivis Guerra, Ángel Pérez Aguiar and Santiago Dueñas-Carrera
Funding Agency and Grant Number
Corresponding author Dr. Yalena Amador-Cañizares, Centro de Ingeniería Genética y Biotecnología, Ave 31, 158 and 190, PO Box 6162, Playa 10600, Havana, Cuba. yalena.amador@cigb.edu.cu
Keywords Clinical trial; DNA vaccine; Enzyme-linked immunospot; Hepatitis C virus; Leukopenia
Core Tip We assayed, for the first time, the concomitant administration of CIGB-230, a DNA-based therapeutic vaccine candidate against hepatitis C virus (HCV), and non-peginterferon-α (IFN-α) plus ribavirin therapy to chronic, treatment-naive, HCV genotype 1b infected patients. We showed that CIGB-230 enhanced the neutralizing antibody response and induced de novo proliferative and IFN-γ secretion responses in the context of antiviral therapy. The quality of the induced immune response depended on both the number of doses and the timing of administration in relation to the antiviral therapy. In particular, the increases in neutralizing antibodies and IFN-γ were associated with the sustained virological response.
Publish Date 2014-01-20 17:10
Citation Amador-Canizares Y, Martínez-Donato G, álvarez-Lajonchere L, Vasallo C, et al. HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin. World J Gastroenterol 2014; 20(1): 148-162
Url http://www.wjgnet.com/1007-9327/full/v20/i1/148.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i1.148
Full Article (PDF) WJG-20-1.pdf
Full Article (Word) WJG-20-1.doc
Manuscript File 2554-Review.doc
Answering Reviewers 2554-Answering reviewers.pdf
Copyright License Agreement 2554-Copyright assignment.pdf
Peer-review Report 2554-Peer review(s).docx
Scientific Editor Work List 2554-Scientific editor work list.doc